All In Biotech

Drug Trial Radar · NCT07686484

A Trial of HRS-3095 in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-3095 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Oct 16, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Jul 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • HRS-3095Drug

    Single dose HRS-3095 /placebo given orally - Dose level 1

  • HRS-3095Drug

    Single dose HRS-3095 /placebo given orally - Dose level 2

  • HRS-3095Drug

    Single dose HRS-3095 /placebo given orally - Dose level 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse EventsTime frame: Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Veritus Research

    Bayswater, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.